The International Society for Bipolar Disorders (ISBD) consensus guidelines for the safety monitoring of bipolar disorder treatments

Bipolar Disorders

Volumn 11, Issue 6, 2009, Pages 559-595

  Ng, Felicity ^a,b,c,d   Mammen, Oommen K ^e   Wilting, Ingeborg ^f,g   Sachs, Gary S ^h,i   Ferrier, I Nicol ^j   Cassidy, Frederick ^k   Beaulieu, Serge ^l,m   Yatham, Lakshmi N ⁿ   Berk, Michael ^c,d,o,p  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b Central Northern Adelaide Health Service   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d BARWON HEALTH   (Australia)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^g UTRECHT UNIVERSITY   (Netherlands)

^h MASSACHUSETTS GENERAL HOSPITAL   (United States)

ⁱ HARVARD MEDICAL SCHOOL   (United States)

^j NEWCASTLE UNIVERSITY   (United Kingdom)

^k DUKE UNIVERSITY MEDICAL CENTER   (United States)

^l MCGILL UNIVERSITY   (Canada)

^m DOUGLAS MENTAL HEALTH UNIVERSITY INSTITUTE   (Canada)

ⁿ UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^o ORYGEN RESEARCH CENTRE   (Australia)

^p FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

more..

Author keywords

Atypical antipsychotics; Bipolar disorder; Guidelines; Iatrogenesis; Lithium; Metabolic; Monitoring; Mood stabilizers; Safety

Indexed keywords

ANTITHROMBOCYTIC AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; CLOZAPINE; CYCLOOXYGENASE 2 INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LAMOTRIGINE; LITHIUM SALT; LOOP DIURETIC AGENT; MOOD STABILIZER; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OLANZAPINE; ORAL CONTRACEPTIVE AGENT; PLACEBO; PROGESTERONE; QUETIAPINE; RISPERIDONE; SERTINDOLE; THIAZIDE DIURETIC AGENT; VALPROIC ACID; ZIPRASIDONE;

ABDOMINAL PAIN; ACNE; ACUTE PANCREATITIS; AGITATION; AGRANULOCYTOSIS; ANOREXIA; APLASTIC ANEMIA; ARTICLE; ATAXIA; BIPOLAR DISORDER; BLOOD DYSCRASIA; BONE DENSITY; BRADYCARDIA; BRAIN DISEASE; BREAST FEEDING; CARDIOMYOPATHY; CARDIOTOXICITY; CLINICAL TRIAL; COGNITIVE DEFECT; COST EFFECTIVENESS ANALYSIS; DEHYDRATION; DIABETES MELLITUS; DIABETIC KETOACIDOSIS; DIARRHEA; DIZZINESS; DROWSINESS; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG MONITORING; DRUG POTENTIATION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; DYSARTHRIA; DYSLIPIDEMIA; ECG ABNORMALITY; ELDERLY CARE; ERYTHEMA MULTIFORME; EXTRAPYRAMIDAL SYMPTOM; FASCICULATION; HAIR LOSS; HEART ARRHYTHMIA; HEART DEPOLARIZATION; HEART REPOLARIZATION; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERAMMONEMIC ENCEPHALOPATHY; HYPERLIPIDEMIA; HYPERPARATHYROIDISM; HYPERPROLACTINEMIA; HYPERTENSION; HYPOFIBRINOGENEMIA; HYPONATREMIA; HYPOTHYROIDISM; INCIDENCE; INTERSTITIAL NEPHRITIS; INTRACRANIAL HYPERTENSION; LETHARGY; LEUKOCYTOSIS; LEUKOPENIA; LIVER TOXICITY; METABOLIC SYNDROME X; MYOCARDITIS; NAUSEA; NEPHROGENIC DIABETES INSIPIDUS; NEPHROTOXICITY; NEUTROPENIA; NONKETOTIC DIABETIC COMA; ORTHOSTATIC HYPOTENSION; OVARY POLYCYSTIC DISEASE; PATIENT MONITORING; POLYDIPSIA; POLYURIA; PRACTICE GUIDELINE; PREGNANCY; PREVALENCE; PRIORITY JOURNAL; PSORIASIS; QT PROLONGATION; RECOMMENDED DRUG DOSE; SCHIZOPHRENIA; SIDE EFFECT; STEVENS JOHNSON SYNDROME; SYNCOPE; TACHYCARDIA; TERATOGENICITY; THROMBOCYTE DYSFUNCTION; THROMBOCYTOPENIA; TORSADE DES POINTES; TOXIC EPIDERMAL NECROLYSIS; TOXIC HEPATITIS; TREATMENT INDICATION; TREMOR; VOMITING; VON WILLEBRAND DISEASE; WEAKNESS; WEIGHT GAIN;

ANTIMANIC AGENTS; BIPOLAR DISORDER; CONSENSUS; HUMANS; MONITORING, PHYSIOLOGIC; SOCIETIES, SCIENTIFIC;

EID: 66649113791     PISSN: 13985647     EISSN: 13995618     Source Type: Journal    
DOI: 10.1111/j.1399-5618.2009.00737.x     Document Type: Article

References (298)

1. Kupfer DJ. The increasing medical burden in bipolar disorder. JAMA 2005; 293: 2528-2530.
2. McIntyre RS, Konarski JZ, Soczynska JK et al. Medical comorbidity in bipolar disorder: Implications for functional outcomes and health service utilization. Psychiatr Serv 2006; 57: 1140-1144.
3. Kilbourne AM, Post EP, Bauer MS et al. Therapeutic drug and cardiovascular disease risk monitoring in patients with bipolar disorder. J Affect Disord 2007; 102: 145-151.
4. Cabana MD, Rand CS, Powe NR et al. Why don't physicians follow clinical practice guidelines? A framework for improvement. JAMA 1999; 282: 1458-1465.
5. Kilbourne AM. The burden of general medical conditions in patients with bipolar disorder. Curr Psychiatry Rep 2005; 7: 471-477.
6. Marder SR, Essock SM, Miller AL et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004; 161: 1334-1349.
7. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists and North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004; 27: 596-601.
8. Expert Group. 'Schizophrenia and Diabetes 2003' Expert Consensus Meeting, Dublin, 3-4 October 2003: Consensus summary. Br J Psychiatry Suppl 2004; 47: S112-S114.
9. Berk M, Fitzsimons J, Lambert T et al. Monitoring the safe use of clozapine: A consensus view from Victoria, Australia. CNS Drugs 2007; 21: 117-127.
10. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002; 159: 1-50.
11. Kowatch RA, Fristad M, Birmaher B, Wagner KD, Findling RL, Hellander M. Treatment guidelines for children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry 2005; 44: 213-235.
12. National Institute for Health and Clinical Excellence (NICE). Bipolar disorder. The management of bipolar disorder in adults, children and adolescents, in primary and secondary care. NICE clinical guideline 38 2006 (cited 2008 December 14); available from: http://www.nice.org.uk/ CG038.
13. Yatham LN, Kennedy SH, O'Donovan C et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: Consensus and controversies. Bipolar Disord 2005; 7 (Suppl. 3): 5-69.
14. Yatham LN, Kennedy SH, O'Donovan C et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: Update 2007. Bipolar Disord 2006; 8: 721-739.
15. Masand PS, Culpepper L, Henderson D et al. Metabolic and endocrine disturbances in psychiatric disorders: A multidisciplinary approach to appropriate atypical antipsychotic utilization. CNS Spectr 2005; 10 (Suppl. 14): 1-15.
16. Birkenaes AB, Opjordsmoen S, Brunborg C et al. The level of cardiovascular risk factors in bipolar disorder equals that of schizophrenia: A comparative study. J Clin Psychiatry 2007; 68: 917-923.
17. Fagiolini A, Frank E, Scott JA, Turkin S, Kupfer DJ. Metabolic syndrome in bipolar disorder: Findings from the Bipolar Disorder Center for Pennsylvanians. Bipolar Disord 2005; 7: 424-430.
18. Kilbourne AM, Cornelius JR, Han X et al. Burden of general medical conditions among individuals with bipolar disorder. Bipolar Disord 2004; 6: 368-373.
19. Osby U, Brandt L, Correia N, Ekbom A, Sparen P. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry 2001; 58: 844-850.
20. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004; 109: 433-438.
21. Fagiolini A, Chengappa KNR. Weight gain and metabolic issues of medicines used for bipolar disorder. Curr Psychiatry Rep 2007; 9: 521-528.
22. Wu RR, Zhao JP, Jin H et al. Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: A randomized controlled trial. JAMA 2008; 299: 185-193.
23. Angst F, Stassen HH, Clayton PJ, Angst J. Mortality of patients with mood disorders: Follow-up over 34-38 years. J Affect Disord 2002; 68: 167-181.
24. American Diabetes Association. Standards of medical care in diabetes - 2007. Diabetes Care 2007; 30 (Suppl. 1): S4-S41.
25. Buell C, Kermah D, Davidson MB. Utility of A1C for diabetes screening in the 1999 2004 NHANES population. Diabetes Care 2007; 30: 2233-2235.
26. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
27. Baldessarini RJ, Tondo L, Hennen J, Viguera AC. Is lithium still worth using? An update of selected recent research. Harv Rev Psychiatry 2002; 10: 59-75.
28. Carney SM, Goodwin GM. Lithium - a continuing story in the treatment of bipolar disorder. Acta Psychiatr Scand Suppl 2005; 426: 7-12.
29. Cipriani A, Pretty H, Hawton K, Geddes JR. Lithium in the prevention of suicidal behavior and all-cause mortality in patients with mood disorders: A systematic review of randomized trials. Am J Psychiatry 2005; 162: 1805-1819.
30. Goodwin FK, Fireman B, Simon GE, Hunkeler EM, Lee J, Revicki D. Suicide risk in bipolar disorder during treatment with lithium and divalproex. JAMA 2003; 290: 1467-1473.
31. Bartha L, Marksteiner J, Bauer G, Benke T. Persistent cognitive deficits associated with lithium intoxication: A neuropsychological case description. Cortex 2002; 38: 743-752.
32. Hansen HE, Amdisen A. Lithium intoxication. (Report of 23 cases and review of 100 cases from the literature). Q J Med 1978; 47: 123-144.
33. Dawson AH, Whyte IM. Therapeutic drug monitoring in drug overdose. Br J Clin Pharmacol 1999; 48: 278-283.
34. Timmer RT, Sands JM. Lithium intoxication. J Am Soc Nephrol 1999; 10: 666-674.
35. Oakley PW, Whyte IM, Carter GL. Lithium toxicity: An iatrogenic problem in susceptible individuals. Aust N Z J Psychiatry 2001; 35: 833-840.
36. Himmelhoch JM, Neil JF, May SJ, Fuchs CZ, Licata SM. Age, dementia, dyskinesias, and lithium response. Am J Psychiatry 1980; 137: 941-945.
37. Delva NJ, Hawken ER. Preventing lithium intoxication. Guide for physicians. Can Fam Physician 2001; 47: 1595-1600.
38. Bell AJ, Cole A, Eccleston D, Ferrier IN. Lithium neurotoxicity at normal therapeutic levels. Br J Psychiatry 1993; 162: 689-692.
39. Fenves AZ, Emmett M, White MG. Lithium intoxication associated with acute renal failure. South Med J 1984; 77: 1472-1474.
40. Boton R, Gaviria M, Batlle DC. Prevalence, pathogenesis, and treatment of renal dysfunction associated with chronic lithium therapy. Am J Kidney Dis 1987; 10: 329-345.
41. Markowitz GS, Radhakrishnan J, Kambham N, Valeri AM, Hines WH, D'Agati VD. Lithium nephrotoxicity: A progressive combined glomerular and tubulointerstitial nephropathy. J Am Soc Nephrol 2000; 11: 1439-1448.
42. Presne C, Fakhouri F, Noel LH et al. Lithium-induced nephropathy: Rate of progression and prognostic factors. Kidney Int 2003; 64: 585-592.
43. Bendz H, Aurell M, Balldin J, Mathe AA, Sjodin I. Kidney damage in long-term lithium patients: A cross-sectional study of patients with 15 years or more on lithium. Nephrol Dial Transplant 1994; 9: 1250-1254.
44. Lepkifker E, Sverdlik A, Iancu I, Ziv R, Segev S, Kotler M. Renal insufficiency in long-term lithium treatment. J Clin Psychiatry 2004; 65: 850-856.
45. Garofeanu CG, Weir M, Rosas-Arellano MP, Henson G, Garg AX, Clark WF. Causes of reversible nephrogenic diabetes insipidus: A systematic review. Am J Kidney Dis 2005; 45: 626-637.
46. Sands JM, Bichet DG. Nephrogenic diabetes insipidus. Ann Intern Med 2006; 144: 186-194.
47. Nielsen J, Kwon TH, Christensen BM, Frokiaer J, Nielsen S. Dysregulation of renal aquaporins and epithelial sodium channel in lithium-induced nephrogenic diabetes insipidus. Semin Nephrol 2008; 28: 227-244.
48. Bucht G, Wahlin A. Renal concentrating capacity in long-term lithium treatment and after withdrawal of lithium. Acta Med Scand 1980; 207: 309-314.
49. Movig KL, Baumgarten R, Leufkens HG, van Laarhoven JH, Egberts AC. Risk factors for the development of lithium-induced polyuria. Br J Psychiatry 2003; 182: 319-323.
50. Bendz H. Kidney function in a selected lithium population. A prospective, controlled, lithium-withdrawal study. Acta Psychiatr Scand 1985; 72: 451-463.
51. Vestergaard P, Amdisen A. Lithium treatment and kidney function. A follow-up study of 237 patients in long-term treatment. Acta Psychiatr Scand 1981; 63: 333-345.
52. Bendz H, Sjodin I, Aurell M. Renal function on and off lithium in patients treated with lithium for 15 years or more. A controlled, prospective lithium-withdrawal study. Nephrol Dial Transplant 1996; 11: 457-460.
53. Thompson CJ, France AJ, Baylis PH. Persistent nephrogenic diabetes insipidus following lithium therapy. Scott Med J 1997; 42: 16-17.
54. Bendz H, Aurell M. Drug-induced diabetes insipidus: Incidence, prevention and management. Drug Saf 1999; 21: 449-456.
55. Crammer JL. Drinking, thirst and water intoxication. Br J Psychiatry 1991; 159: 83-89.
56. Vanderpump MP, Tunbridge WM, French JM et al. The incidence of thyroid disorders in the community: A twenty-year follow-up of the Whickham Survey. Clin Endocrinol (Oxf) 1995; 43: 55-68.
57. Bocchetta A, Mossa P, Velluzzi F, Mariotti S, Zompo MD, Loviselli A. Ten-year follow-up of thyroid function in lithium patients. J Clin Psychopharmacol 2001; 21: 594-598.
58. Johnston AM, Eagles JM. Lithium-associated clinical hypothyroidism. Prevalence and risk factors. Br J Psychiatry 1999; 175: 336-339.
59. Kupka RW, Nolen WA, Post RM et al. High rate of autoimmune thyroiditis in bipolar disorder: Lack of association with lithium exposure. Biol Psychiatry 2002; 51: 305-311.
60. Kirov G, Tredget J, John R, Owen MJ, Lazarus JH. A cross-sectional and a prospective study of thyroid disorders in lithium-treated patients. J Affect Disord 2005; 87: 313-317.
61. Chopra IJ, Solomon DH, Huang TS. Serum thyrotropin in hospitalized psychiatric patients: Evidence for hyperthyrotropinemia as measured by an ultrasensitive thyrotropin assay. Metabolism 1990; 39: 538-543.
62. Maarbjerg K, Vestergaard P, Schou M. Changes in serum thyroxine (T4) and serum thyroid stimulating hormone (TSH) during prolonged lithium treatment. Acta Psychiatr Scand 1987; 75: 217-221.
63. Spratt DI, Pont A, Miller MB, McDougall IR, Bayer MF, McLaughlin WT. Hyperthyroxinemia in patients with acute psychiatric disorders. Am J Med 1982; 73: 41-48.
64. Awad SS, Miskulin J, Thompson N. Parathyroid adenomas versus four-gland hyperplasia as the cause of primary hyperparathyroidism in patients with prolonged lithium therapy. World J Surg 2003; 27: 486-488.
65. Bendz H, Sjodin I, Toss G, Berglund K. Hyperparathyroidism and long-term lithium therapy-a cross-sectional study and the effect of lithium withdrawal. J Intern Med 1996; 240: 357-365.
66. Haden ST, Stoll AL, McCormick S, Scott J, Fuleihan Ge-H. Alterations in parathyroid dynamics in lithium-treated subjects. J Clin Endocrinol Metab 1997; 82: 2844-2848.
67. Lienert D, Rege S. Moans, stones, groans, bones and psychiatric overtones: Lithium-induced hyperparathyroidism. Aust N Z J Psychiatry 2008; 42: 171-173.
68. Younes NA, Shafagoj Y, Khatib F, Ababneh M. Laboratory screening for hyperparathyroidism. Clin Chim Acta 2005; 353: 1-12.
69. Sachs G, Bowden C, Calabrese JR et al. Effects of lamotrigine and lithium on body weight during maintenance treatment of bipolar I disorder. Bipolar Disord 2006; 8: 175-181.
70. Bowden CL, Calabrese JR, Ketter TA, Sachs GS, White RL, Thompson TR. Impact of lamotrigine and lithium on weight in obese and nonobese patients with bipolar I disorder. Am J Psychiatry 2006; 163: 1199-1201.
71. Vendsborg PB, Bech P, Rafaelsen OJ. Lithium treatment and weight gain. Acta Psychiatr Scand 1976; 53: 139-147.
72. Vestergaard P, Poulstrup I, Schou M. Prospective studies on a lithium cohort. 3. Tremor, weight gain, diarrhea, psychological complaints. Acta Psychiatr Scand 1988; 78: 434-441.
73. Phelan KM, Mosholder AD, Lu S. Lithium interaction with the cyclooxygenase 2 inhibitors rofecoxib and celecoxib and other nonsteroidal anti-inflammatory drugs. J Clin Psychiatry 2003; 64: 1328-1334.
74. Finley PR, Warner MD, Peabody CA. Clinical relevance of drug interactions with lithium. Clin Pharmacokinet 1995; 29: 172-191.
75. Meyer JM, Dollarhide A, Tuan IL. Lithium toxicity after switch from fosinopril to lisinopril. Int Clin Psychopharmacol 2005; 20: 115-118.
76. Johnson G. Lithium-early development, toxicity, and renal function. Neuropsychopharmacology 1998; 19: 200-205.
77. Bocchetta A, Loviselli A. Lithium treatment and thyroid abnormalities. Clin Pract Epidemol Ment Health 2006; 2: 23.
78. Cho H-S, Krystal J, D'Souza DC. Blood dyscrasias. In: Haddad PM, Dursun S, Deakin B, ed. Adverse Syndromes and Psychiatric Drugs: A Clinical Guide. Oxford, UK: Oxford University Press, 2004: 221-238.
79. Harden CL. Therapeutic safety monitoring: What to look for and when to look for it. Epilepsia 2000; 41 (Suppl. 8): S37-S44.
80. Sobotka JL, Alexander B, Cook BL. A review of carbamazepine's hematologic reactions and monitoring recommendations. DICP 1990; 24: 1214-1219.
81. Tohen M, Castillo J, Baldessarini RJ, Zarate C Jr, Kando JC. Blood dyscrasias with carbamazepine and valproate: A pharmacoepidemiological study of 2,228 patients at risk. Am J Psychiatry 1995; 152: 413-418.
82. Andres E, Maloisel F. Idiosyncratic drug-induced agranulocytosis or acute neutropenia. Curr Opin Hematol 2008; 15: 15-21.
83. Brodsky RA, Jones RJ. Aplastic anaemia. Lancet 2005; 365: 1647-1656.
84. Andersohn F, Konzen C, Garbe E. Systematic review: Agranulocytosis induced by nonchemotherapy drugs. Ann Intern Med 2007; 146: 657-665.
85. Handoko KB, Souverein PC, van Staa TP et al. Risk of aplastic anemia in patients using antiepileptic drugs. Epilepsia 2006; 47: 1232-1236.
86. Kaufman DW, Kelly JP, Jurgelon JM et al. Drugs in the aetiology of agranulocytosis and aplastic anaemia. Eur J Haematol Suppl 1996; 60: 23-30.
87. Cates M, Powers R. Concomitant rash and blood dyscrasias in geriatric psychiatry patients treated with carbamazepine. Ann Pharmacother 1998; 32: 884-887.
88. Ganeva M, Gancheva T, Lazarova R et al. Carbamazepine-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: report of four cases and brief review. Int J Dermatol 2008; 47: 853-860.
89. Blackburn SC, Oliart AD, Garcia Rodriguez LA, Perez Gutthann S. Antiepileptics and blood dyscrasias: A cohort study. Pharmacotherapy 1998; 18: 1277-1283.
90. Acharya S, Bussel JB. Hematologic toxicity of sodium valproate. J Pediatr Hematol Oncol 2000; 22: 62-65.
91. Conley EL, Coley KC, Pollock BG, Dapos SV, Maxwell R, Branch RA. Prevalence and risk of thrombocytopenia with valproic acid: Experience at a psychiatric teaching hospital. Pharmacotherapy 2001; 21: 1325-1330.
92. Gerstner T, Teich M, Bell N et al. Valproate-associated coagulopathies are frequent and variable in children. Epilepsia 2006; 47: 1136-1143.
93. Callaghan N, Majeed T, O'Connell A, Oliveira DB. A comparative study of serum F protein and other liver function tests as an index of hepatocellular damage in epileptic patients. Acta Neurol Scand 1994; 89: 237-241.
94. Pellock JM. Carbamazepine side effects in children and adults. Epilepsia 1987; 28 (Suppl. 3): S64-S70.
95. Abboud G, Kaplowitz N. Drug-induced liver injury. Drug Saf 2007; 30: 277-294.
96. Benichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol 1990; 11: 272-276.
97. Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med 2006; 354: 731-739.
98. Dreifuss FE, Langer DH. Hepatic considerations in the use of antiepileptic drugs. Epilepsia 1987; 28 (Suppl. 2): S23-S29.
99. Pirmohamed M, Leeder SJ. Anticonvulsant agents. In: Kaplowitz N, DeLeve LD, ed. Drug-Induced Liver Disease. New York: Informa Health Care, 2007: 485-506.
100. de Abajo FJ, Montero D, Madurga M, Garcia Rodriguez LA. Acute and clinically relevant drug-induced liver injury: A population based case-control study. Br J Clin Pharmacol 2004; 58: 71-80.
101. Powell-Jackson PR, Tredger JM, Williams R. Hepatotoxicity to sodium valproate: A review. Gut 1984; 25: 673-681.
102. Wyllie E, Wyllie R. Routine laboratory monitoring for serious adverse effects of antiepileptic medications: The controversy. Epilepsia 1991; 32 (Suppl. 5): S74-S79.
103. Bryant AE III, Dreifuss FE. Valproic acid hepatic fatalities. III. U.S. experience since 1986. Neurology 1996; 46: 465-469.
104. Dreifuss FE, Santilli N, Langer DH, Sweeney KP, Moline KA, Menander KB. Valproic acid hepatic fatalities: A retrospective review. Neurology 1987; 37: 379-385.
105. Wolf R, Matz H, Marcos B, Orion E. Drug rash with eosinophilia and systemic symptoms vs toxic epidermal necrolysis: The dilemma of classification. Clin Dermatol 2005; 23: 311-314.
106. Al-Johani KA, Fedele S, Porter SR. Erythema multiforme and related disorders. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007; 103: 642-654.
107. Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 1993; 129: 92-96.
108. Pereira FA, Mudgil AV, Rosmarin DM. Toxic epidermal necrolysis. J Am Acad Dermatol 2007; 56: 181-200.
109. Auquier-Dunant A, Mockenhaupt M, Naldi L, Correia O, Schroder W, Roujeau JC. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: Results of an international prospective study. Arch Dermatol 2002; 138: 1019-1024.
110. Schneck J, Fagot JP, Sekula P, Sassolas B, Roujeau JC, Mockenhaupt M. Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: A retrospective study on patients included in the prospective EuroSCAR Study. J Am Acad Dermatol 2008; 58: 33-40.
111. Mockenhaupt M, Messenheimer J, Tennis P, Schlingmann J. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics. Neurology 2005; 64: 1134-1138.
112. Roujeau JC, Kelly JP, Naldi L et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995; 333: 1600-1607.
113. Rzany B, Correia O, Kelly JP, Naldi L, Auquier A, Stern R. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: A case-control study. Study Group of the International Case Control Study on Severe Cutaneous Adverse Reactions. Lancet 1999; 353: 2190-2194.
114. Bowden CL, Asnis GM, Ginsberg LD, Bentley B, Leadbetter R, White R. Safety and tolerability of lamotrigine for bipolar disorder. Drug Saf 2004; 27: 173-184.
115. Calabrese JR, Sullivan JR, Bowden CL et al. Rash in multicenter trials of lamotrigine in mood disorders: Clinical relevance and management. J Clin Psychiatry 2002; 63: 1012-1019.
116. Guberman AH, Besag FM, Brodie MJ et al. Lamotrigine-associated rash: risk/benefit considerations in adults and children. Epilepsia 1999; 40: 985-991.
117. Petty SJ, O'Brien TJ, Wark JD. Anti-epileptic medication and bone health. Osteoporos Int 2007; 18: 129-142.
118. Mauck KF, Clarke BL. Diagnosis, screening, prevention, and treatment of osteoporosis. Mayo Clin Proc 2006; 81: 662-672.
119. Trevathan E. Epilepsy-associated bone mineral density loss should be prevented. Neurology 2008; 70: 166-167.
120. Dong X, Leppik IE, White J, Rarick J. Hyponatremia from oxcarbazepine and carbamazepine. Neurology 2005; 65: 1976-1978.
121. Van Amelsvoort T, Bakshi R, Devaux CB, Schwabe S. Hyponatremia associated with carbamazepine and oxcarbazepine therapy: A review. Epilepsia 1994; 35: 181-188.
122. Asconape JJ. Some common issues in the use of antiepileptic drugs. Semin Neurol 2002; 22: 27-39.
123. Adrogue HJ. Consequences of inadequate management of hyponatremia. Am J Nephrol 2005; 25: 240-249.
124. Decaux G. Is asymptomatic hyponatremia really asymptomatic? Am J Med 2006; 119: S79-S82.
125. Gandelman MS. Review of carbamazepine-induced hyponatremia. Prog Neuropsychopharmacol Biol Psychiatry 1994; 18: 211-233.
126. Siegel AJ. Hyponatremia in psychiatric patients: Update on evaluation and management. Harv Rev Psychiatry 2008; 16: 13-24.
127. Biton V. Effect of antiepileptic drugs on bodyweight: Overview and clinical implications for the treatment of epilepsy. CNS Drugs 2003; 17: 781-791.
128. Steinhoff BJ, Ueberall MA, Siemes H, Kurlemann G, Schmitz B, Bergmann L. The LAM-SAFE Study: Lamotrigine versus carbamazepine or valproic acid in newly diagnosed focal and generalised epilepsies in adolescents and adults. Seizure 2005; 14: 597-605.
129. Privitera MD, Brodie MJ, Mattson RH, Chadwick DW, Neto W, Wang S. Topiramate, carbamazepine and valproate monotherapy: Double-blind comparison in newly diagnosed epilepsy. Acta Neurol Scand 2003; 107: 165-175.
130. Biton V, Mirza W, Montouris G, Vuong A, Hammer AE, Barrett PS. Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy. Neurology 2001; 56: 172-177.
131. Bowden CL, Calabrese JR, McElroy SL et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch Gen Psychiatry 2000; 57: 481-489.
132. Zajecka JM, Weisler R, Sachs G, Swann AC, Wozniak P, Sommerville KW. A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder. J Clin Psychiatry 2002; 63: 1148-1155.
133. Tohen M, Ketter TA, Zarate CA et al. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: A 47-week study. Am J Psychiatry 2003; 160: 1263-1271.
134. Norman RJ, Dewailly D, Legro RS, Hickey TE. Polycystic ovary syndrome. Lancet 2007; 370: 685-697.
135. Setji TL, Brown AJ. Polycystic ovary syndrome: Diagnosis and treatment. Am J Med 2007; 120: 128-132.
136. Joffe H, Cohen LS, Suppes T et al. Valproate is associated with new-onset oligoamenorrhea with hyperandrogenism in women with bipolar disorder. Biol Psychiatry 2006; 59: 1078-1086.
137. Joffe H, Cohen LS, Suppes T et al. Longitudinal follow-up of reproductive and metabolic features of valproate-associated polycystic ovarian syndrome features: A preliminary report. Biol Psychiatry 2006; 60: 1378-1381.
138. Isojarvi JI, Rattya J, Myllyla VV et al. Valproate, lamotrigine, and insulin-mediated risks in women with epilepsy. Ann Neurol 1998; 43: 446-451.
139. Pylvanen V, Knip M, Pakarinen AJ et al. Fasting serum insulin and lipid levels in men with epilepsy. Neurology 2003; 60: 571-574.
140. Roste LS, Tauboll E, Morkrid L et al. Antiepileptic drugs alter reproductive endocrine hormones in men with epilepsy. Eur J Neurol 2005; 12: 118-124.
141. Stephen LJ, Kwan P, Shapiro D, Dominiczak M, Brodie MJ. Hormone profiles in young adults with epilepsy treated with sodium valproate or lamotrigine monotherapy. Epilepsia 2001; 42: 1002-1006.
142. Gerstner T, Busing D, Bell N et al. Valproic acid-induced pancreatitis: 16 new cases and a review of the literature. J Gastroenterol 2007; 42: 39-48.
143. Werlin SL, Fish DL. The spectrum of valproic acid-associated pancreatitis. Pediatrics 2006; 118: 1660-1663.
144. Pellock JM, Wilder BJ, Deaton R, Sommerville KW. Acute pancreatitis coincident with valproate use: A critical review. Epilepsia 2002; 43: 1421-1424.
145. Segura-Bruna N, Rodriguez-Campello A, Puente V, Roquer J. Valproate-induced hyperammonemic encephalopathy. Acta Neurol Scand 2006; 114: 1-7.
146. Gomceli YB, Kutlu G, Cavdar L, Sanivar F, Inan LE. Different clinical manifestations of hyperammonemic encephalopathy. Epilepsy Behav 2007; 10: 583-587.
147. O'Brien MD, Guillebaud J. Contraception for women with epilepsy. Epilepsia 2006; 47: 1419-1422.
148. Teal SB, Ginosar DM. Contraception for women with chronic medical conditions. Obstet Gynecol Clin North Am 2007; 34: 113-126. ix.
149. Jarema M. Atypical antipsychotics in the treatment of mood disorders. Curr Opin Psychiatry 2007; 20: 23-29.
150. Scherk H, Pajonk FG, Leucht S. Second-generation antipsychotic agents in the treatment of acute mania: A systematic review and meta-analysis of randomized controlled trials. Arch Gen Psychiatry 2007; 64: 442-455.
151. Feinstein RE. Cardiovascular effects of novel antipsychotic medications. Heart Dis 2002; 4: 184-190.
152. Correll CU, Frederickson AM, Kane JM, Manu P. Does antipsychotic polypharmacy increase the risk for metabolic syndrome? Schizophr Res 2007; 89: 91-100.
153. Citrome LL, Holt RI, Zachry WM et al. Risk of treatment-emergent diabetes mellitus in patients receiving antipsychotics. Ann Pharmacother 2007; 41: 1593-1603.
154. Gianfrancesco F, Wang RH, Nasrallah HA. The influence of study design on the results of pharmacoepidemiologic studies of diabetes risk with antipsychotic therapy. Ann Clin Psychiatry 2006; 18: 9-17.
155. Newcomer JW. Metabolic considerations in the use of antipsychotic medications: A review of recent evidence. J Clin Psychiatry 2007; 68 (Suppl. 1): 20-27.
156. Allison DB, Mentore JL, Heo M et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999; 156: 1686-1696.
157. Lieberman JA, Stroup TS, McEvoy JP et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209-1223.
158. Newcomer JW. Antipsychotic medications: Metabolic and cardiovascular risk. J Clin Psychiatry 2007; 68 (Suppl. 4): 8-13.
159. Meltzer HY. Focus on the metabolic consequences of long-term treatment with olanzapine, quetiapine and risperidone: Are there differences? Int J Neuropsychopharmacol 2005; 8: 153-156.
160. Olfson M, Marcus SC, Corey-Lisle P, Tuomari AV, Hines P, L'Italien GJ. Hyperlipidemia following treatment with antipsychotic medications. Am J Psychiatry 2006; 163: 1821-1825.
161. Bushe CJ, Leonard BE. Blood glucose and schizophrenia: A systematic review of prospective randomized clinical trials. J Clin Psychiatry 2007; 68: 1682-1690.
162. Guo JJ, Keck PE Jr, Corey-Lisle PK et al. Risk of diabetes mellitus associated with atypical antipsychotic use among patients with bipolar disorder: A retrospective, population-based, case-control study. J Clin Psychiatry 2006; 67: 1055-1061.
163. Guo JJ, Keck PE Jr, Corey-Lisle PK et al. Risk of diabetes mellitus associated with atypical antipsychotic use among Medicaid patients with bipolar disorder: A nested case-control study. Pharmacotherapy 2007; 27: 27-35.
164. Henderson DC, Cagliero E, Copeland PM et al. Elevated hemoglobin A1c as a possible indicator of diabetes mellitus and diabetic ketoacidosis in schizophrenia patients receiving atypical antipsychotics. J Clin Psychiatry 2007; 68: 533-541.
165. Varma MK, Connolly K, Fulton B. Life-threatening hyperglycemia and acidosis related to olanzapine: A case report and review of the literature. J Intensive Care Med 2007; 22: 52-55.
166. Church CO, Stevens DL, Fugate SE. Diabetic ketoacidosis associated with aripiprazole. Diabet Med 2005; 22: 1440-1443.
167. Reddymasu S, Bahta E, Levine S, Manas K, Slay LE. Elevated lipase and diabetic ketoacidosis associated with aripiprazole. JOP 2006; 7: 303-305.
168. Dibben CR, Kalavalapalli SS, Linnington HE et al. Diabetes associated with atypical antipsychotic treatment may be severe but reversible: Case report. Int J Psychiatry Med 2005; 35: 307-311.
169. Mackin P. Cardiac side effects of psychiatric drugs. Hum Psychopharmacol 2008; 23 (Suppl. 1): 3-14.
170. Coulter DM, Bate A, Meyboom RH, Lindquist M, Edwards IR. Antipsychotic drugs and heart muscle disorder in international pharmacovigilance: Data mining study. BMJ 2001; 322: 1207-1209.
171. Fitzsimons J, Berk M, Lambert T, Bourin M, Dodd S. A review of clozapine safety. Expert Opin Drug Saf 2005; 4: 731-744.
172. Haas SJ, Hill R, Krum H et al. Clozapine-associated myocarditis: A review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993-2003. Drug Saf 2007; 30: 47-57.
173. Kilian JG, Kerr K, Lawrence C, Celermajer DS. Myocarditis and cardiomyopathy associated with clozapine. Lancet 1999; 354: 1841-1845.
174. Glassman AH, Bigger JT Jr. Antipsychotic drugs: Prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry 2001; 158: 1774-1782.
175. Gupta A, Lawrence AT, Krishnan K, Kavinsky CJ, Trohman RG. Current concepts in the mechanisms and management of drug-induced QT prolongation and torsade de pointes. Am Heart J 2007; 153: 891-899.
176. Shah RR. Pharmacogenetic aspects of drug-induced torsade de pointes: potential tool for improving clinical drug development and prescribing. Drug Saf 2004; 27: 145-172.
177. Witchel HJ, Hancox JC, Nutt DJ. Psychotropic drugs, cardiac arrhythmia, and sudden death. J Clin Psychopharmacol 2003; 23: 58-77.
178. Al-Khatib SM, LaPointe NM, Kramer JM, Califf RM. What clinicians should know about the QT interval. JAMA 2003; 289: 2120-2127.
179. Molnar J, Zhang F, Weiss J, Ehlert FA, Rosenthal JE. Diurnal pattern of QTc interval: How long is prolonged? Possible relation to circadian triggers of cardiovascular events. J Am Coll Cardiol 1996; 27: 76-83.
180. Liu BA, Juurlink DN. Drugs and the QT interval - Caveat doctor. N Engl J Med 2004; 351: 1053-1056.
181. Moss AJ. Long QT Syndrome. JAMA 2003; 289: 2041-2044.
182. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research. Guidance for Industry: E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs. 2005 (cited 2008 June 9); available from: http://www.fda.gov/cder/Guidance/6922fnl.pdf.
183. Harrigan EP, Miceli JJ, Anziano R et al. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharmacol 2004; 24: 62-69.
184. Pfizer. 2007 (cited 2008 December 8); available from: http://www.pfizer.com/pfizer/download/uspi_geodon.pdf.
185. Swainston Harrison T, Perry CM. Aripiprazole: A review of its use in schizophrenia and schizoaffective disorder. Drugs 2004; 64: 1715-1736.
186. Strom BL, Faich GA, Reynolds RF et al. The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC): Design and baseline subject characteristics. J Clin Psychiatry 2008; 69: 114-121.
187. Strom B, Faich G, Eng S et al. Comparative mortality associated with ziprasidone vs. olanzapine in real-world use: The ziprasidone observational study of cardiac outcomes (ZODIAC). Schizophr Res 2008; 98 (Suppl.): 160-161.
188. Zeltser D, Justo D, Halkin A, Prokhorov V, Heller K, Viskin S. Torsade de pointes due to noncardiac drugs: Most patients have easily identifiable risk factors. Medicine (Baltimore) 2003; 82: 282-290.
189. Byerly M, Suppes T, Tran QV, Baker RA. Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: Recent developments and current perspectives. J Clin Psychopharmacol 2007; 27: 639-661.
190. Mancini T, Casanueva FF, Giustina A. Hyperprolactinemia and prolactinomas. Endocrinol Metab Clin North Am 2008; 37: 67-99. viii.
191. Misra M, Papakostas GI, Klibanski A. Effects of psychiatric disorders and psychotropic medications on prolactin and bone metabolism. J Clin Psychiatry 2004; 65: 1607-1618.
192. Szarfman A, Tonning JM, Levine JG, Doraiswamy PM. Atypical antipsychotics and pituitary tumors: A pharmacovigilance study. Pharmacotherapy 2006; 26: 748-758.
193. Flanagan RJ, Dunk L. Haematological toxicity of drugs used in psychiatry. Hum Psychopharmacol 2008; 23 (Suppl. 1): 27-41.
194. Stubner S, Grohmann R, Engel R et al. Blood dyscrasias induced by psychotropic drugs. Pharmacopsychiatry 2004; 37 (Suppl. 1): S70-S78.
195. Pierre JM. Extrapyramidal symptoms with atypical antipsychotics: incidence, prevention and management. Drug Saf 2005; 28: 191-208.
196. Shirzadi AA, Ghaemi SN. Side effects of atypical antipsychotics: extrapyramidal symptoms and the metabolic syndrome. Harv Rev Psychiatry 2006; 14: 152-164.
197. Weiden PJ. EPS profiles: The atypical antipsychotics are not all the same. J Psychiatr Pract 2007; 13: 13-24.
198. van Harten PN, Hoek HW, Kahn RS. Acute dystonia induced by drug treatment. BMJ 1999; 319: 623-626.
199. Castle D, Lambert T, Melbourne S et al. A clinical monitoring system for clozapine. Australas Psychiatry 2006; 14: 156-168.
200. De Hert M, van Eyck D, De Nayer A. Metabolic abnormalities associated with second generation antipsychotics: Fact or fiction? Development of guidelines for screening and monitoring. Int Clin Psychopharmacol 2006; 21 (Suppl. 2): S11-S15.
201. De Nayer A, De Hert M, Scheen A, Van Gaal L, Peuskens J, on behalf of the Consensus Group. Belgian consensus on metabolic problems associated with atypical antipsychotics. Int J Psychiatry Clin Pract 2005; 9: 130-137.
202. Lambert TJ, Chapman LH. Diabetes, psychotic disorders and antipsychotic therapy: A consensus statement. Med J Aust 2004; 181: 544-548.
203. Masand PS, Fazal FS, Patkar AA. Safety considerations in pharmacotherapy of bipolar disorder. CNS Spectr 2004; 9: 16-26.
204. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology-drug disposition, action, and therapy in infants and children. N Engl J Med 2003; 349: 1157-1167.
205. Martin A, Shader R, Oesterheld J. Clinical practice and pharmacokinetic principles. in: Martin A, Volkmar FR, ed. Lewis' Child and Adolescent Psychiatry: A Comprehensive Textbook. Baltimore: Lippincott Williams & Wilkins, 2007: 742-754.
206. Gilman JT, Duchowny M, Campo AE. Pharmacokinetic considerations in the treatment of childhood epilepsy. Paediatr Drugs 2003; 5: 267-277.
207. Vitiello B, Behar D, Malone R, Delaney MA, Ryan PJ, Simpson GM. Pharmacokinetics of lithium carbonate in children. J Clin Psychopharmacol 1988; 8: 355-359.
208. Scahill L, Martin A. Specific drug treatments. in: Martin A, Volkmar FR, ed. Lewis'Child and Adolescent Psychiatry: A Comprehensive Textbook. Baltimore: Lippincott Williams & Wilkins, 2007: 754-789.
209. Birmaher B, Axelson D. Bipolar disorder. In: Martin A, Volkmar FR, ed. Lewis'Child and Adolescent Psychiatry: A Comprehensive Textbook. Baltimore: Lippincott Williams & Wilkins, 2007: 513-526.
210. Greenhill LL, Vitiello B, Riddle MA et al. Review of safety assessment methods used in pediatric psychopharmacology. J Am Acad Child Adolesc Psychiatry 2003; 42: 627-633.
211. Gleason MM, Egger HL, Emslie GJ et al. Psychopharmacological treatment for very young children: Contexts and guidelines. J Am Acad Child Adolesc Psychiatry 2007; 46: 1532-1572.
212. Azorin JM, Findling RL. Valproate use in children and adolescents with bipolar disorder. CNS Drugs 2007; 21: 1019-1033.
213. Correll CU. Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents. J Clin Psychiatry 2008; 69 (Suppl. 4): 26-36.
214. Correll CU, Carlson HE. Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. J Am Acad Child Adolesc Psychiatry 2006; 45: 771-791.
215. Silva RR, Campbell M, Golden RR, Small AM, Pataki CS, Rosenberg CR. Side effects associated with lithium and placebo administration in aggressive children. Psychopharmacol Bull 1992; 28: 319-326.
216. Culy CR, Goa KL. Lamotrigine. A review of its use in childhood epilepsy. Paediatr Drugs 2000; 2: 299-330.
217. McClellan J, Kowatch R, Findling RL. Practice parameter for the assessment and treatment of children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry 2007; 46: 107-125.
218. Labellarte MJ, Crosson JE, Riddle MA. The relevance of prolonged QTc measurement to pediatric psychopharmacology. J Am Acad Child Adolesc Psychiatry 2003; 42: 642-650.
219. Schou M, Goldfield MD, Weinstein MR, Villeneuve A. Lithium and pregnancy. I. Report from the Register of Lithium Babies. Br Med J 1973; 2: 135-136.
220. Cohen LS, Friedman JM, Jefferson JW, Johnson EM, Weiner ML. A reevaluation of risk of in utero exposure to lithium. JAMA 1994, 271: 146-150.
221. Yonkers KA, Wisner KL, Stowe Z et al. Management of bipolar disorder during pregnancy and the postpartum period. Am J Psychiatry 2004; 161: 608-620.
222. Jacobson SJ, Jones K, Johnson K et al. Prospective multicentre study of pregnancy outcome after lithium exposure during first trimester. Lancet 1992; 339: 530-533.
223. Schou M. What happened later to the lithium babies? A follow-up study of children born without malformations. Acta Psychiatr Scand 1976; 54: 193-197.
224. Kozma C. Neonatal toxicity and transient neurodevelopmental deficits following prenatal exposure to lithium: Another clinical report and a review of the literature. Am J Med Genet A 2005; 132: 441-444.
225. Newport DJ, Viguera AC, Beach AJ, Ritchie JC, Cohen LS, Stowe ZN. Lithium placental passage and obstetrical outcome: Implications for clinical management during late pregnancy. Am J Psychiatry 2005; 162: 2162-2170.
226. Viguera AC, Newport DJ, Ritchie J et al. Lithium in breast milk and nursing infants: Clinical implications. Am J Psychiatry 2007; 164: 342-345.
227. Moretti ME, Koren G, Verjee Z, Ito S. Monitoring lithium in breast milk: an individualized approach for breast-feeding mothers. Ther Drug Monit 2003; 25: 364-366.
228. Perucca E. Birth defects after prenatal exposure to antiepileptic drugs. Lancet Neurol 2005; 4: 781-786.
229. Wyszynski DF, Nambisan M, Surve T, Alsdorf RM, Smith CR, Holmes LB. Increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology 2005; 64: 961-965.
230. Genton P, Semah F, Trinka E. Valproic acid in epilepsy: pregnancy-related issues. Drug Saf 2006; 29: 1-21.
231. Koren G, Nava-Ocampo AA, Moretti ME, Sussman R, Nulman I. Major malformations with valproic acid. Can Fam Physician 2006; 52: 441-442. 444, 447.
232. Yerby MS. Management issues for women with epilepsy: Neural tube defects and folic acid supplementation. Neurology 2003; 61 (Suppl. 2): S23-S26.
233. Meador KJ, Baker G, Cohen MJ, Gaily E, Westerveld M. Cognitive/ behavioral teratogenetic effects of antiepileptic drugs. Epilepsy Behav 2007; 11: 292-302.
234. Rasalam AD, Hailey H, Williams JH et al. Characteristics of fetal anticonvulsant syndrome associated autistic disorder. Dev Med Child Neurol 2005; 47: 551-555.
235. Kaaja E, Kaaja R, Hiilesmaa V. Major malformations in offspring of women with epilepsy. Neurology 2003; 60: 575-579.
236. Lindhout D, Omtzigt JG. Teratogenic effects of antiepileptic drugs: implications for the management of epilepsy in women of childbearing age. Epilepsia 1994; 35 (Suppl. 4): S19-S28.
237. Adams JM, Janulewicz PA, Gavin JA. The structural and functional teratology of antiepileptic medications. in: Bellinger D, ed. Human Developmental Neurotoxicology. New York: Taylor and Francis, 2006: 103-131.
238. Gaily E, Kantola-Sorsa E, Hiilesmaa V et al. Normal intelligence in children with prenatal exposure to carbamazepine. Neurology 2004; 62: 28-32.
239. Hernandez-Diaz S, Werler MM, Walker AM, Mitchell AA. Neural tube defects in relation to use of folic acid antagonists during pregnancy. Am J Epidemiol 2001; 153: 961-968.
240. Crawford P. Best practice guidelines for the management of women with epilepsy. Epilepsia 2005; 46 (Suppl. 9): 117-124.
241. Kaaja E, Kaaja R, Matila R, Hiilesmaa V. Enzyme-inducing antiepileptic drugs in pregnancy and the risk of bleeding in the neonate. Neurology 2002; 58: 549-553.
242. American Academy of Pediatrics Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics 2001; 108: 776-789.
243. Chaudron LH, Jefferson JW. Mood stabilizers during breastfeeding: A review. J Clin Psychiatry 2000; 61: 79-90.
244. Stahl MM, Neiderud J, Vinge E. Thrombocytopenic purpura and anemia in a breast-fed infant whose mother was treated with valproic acid. J Pediatr 1997; 130: 1001-1003.
245. Piontek CM, Baab S, Peindl KS, Wisner KL. Serum valproate levels in 6 breastfeeding mother-infant pairs. J Clin Psychiatry 2000; 61: 170-172.
246. Frey B, Braegger CP, Ghelfi D. Neonatal cholestatic hepatitis from carbamazepine exposure during pregnancy and breast feeding. Ann Pharmacother 2002; 36: 644-647.
247. Meador KJ, Baker GA, Finnell RH et al. In utero antiepileptic drug exposure: Fetal death and malformations. Neurology 2006; 67: 407-412.
248. Cunnington M, Tennis P. Lamotrigine and the risk of malformations in pregnancy. Neurology 2005; 64: 955-960.
249. Morrow J, Russell A, Guthrie E et al. Malformation risks of antiepileptic drugs in pregnancy: A prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry 2006; 77: 193-198.
250. Holmes LB, Wyszynski DF, Baldwin EJ, Habecker E, Glassman LH, Smith CR. Increased risk for non-syndromic cleft palate among infants exposed to lamotrigine during pregnancy. Birth Defects Res A Clin Mol Teratol 2006; 76: 318.
251. GlaxoSmithKline. The Lamotrigine Pregnancy Registry. Interim report 1 September 1992 through 31 March 2008. 2008 (cited 2008 December 15); available from: http://www.pregnancyregistry.gsk.com/documents/ lam_report_spring2008.doc.
252. Neurodevelopmental Effects of Antiepileptic Drugs (NEAD) Study. (cited 2008 December 15); available from: http://www.web.emmes.com/study/nead/ index.htm.
253. Pennell PB, Newport DJ, Stowe ZN, Helmers SL, Montgomery JQ, Henry TR. The impact of pregnancy and childbirth on the metabolism of lamotrigine. Neurology 2004; 62: 292-295.
254. Dubnov-Raz G, Shapiro R, Merlob P. Maternal lamotrigine treatment and elevated neonatal gamma-glutamyl transpeptidase. Pediatr Neurol 2006; 35: 220-222.
255. Rubin ET, Lee A, Ito S. When breastfeeding mothers need CNS-acting drugs. Can J Clin Pharmacol 2004; 11: E257-e266.
256. Coppola D, Russo LJ, Kwarta RF Jr, Varughese R, Schmider J. Evaluating the postmarketing experience of risperidone use during pregnancy: pregnancy and neonatal outcomes. Drug Saf 2007; 30: 247-264.
257. Goldstein DJ, Corbin LA, Fung MC. Olanzapine-exposed pregnancies and lactation: Early experience. J Clin Psychopharmacol 2000; 20: 399-403.
258. McKenna K, Koren G, Tetelbaum M et al. Pregnancy outcome of women using atypical antipsychotic drugs: A prospective comparative study. J Clin Psychiatry 2005; 66: 444-449.
259. Newport DJ, Calamaras MR, DeVane CL et al. Atypical antipsychotic administration during late pregnancy: Placental passage and obstetrical outcomes. Am J Psychiatry 2007; 164: 1214-1220.
260. Wisner KL, Sit DK, Moses EL. Antipsychotic treatment during pregnancy: A model for decision making. Adv Schizophrenia Clin Psych 2007; 3: 48-55.
261. Gentile S. Infant safety with antipsychotic therapy in breast-feeding: A systematic review. J Clin Psychiatry 2008; 69: 666-673.
262. Stowe ZN. The use of mood stabilizers during breastfeeding. J Clin Psychiatry 2007; 68 (Suppl. 9): 22-28.
263. Shor S, Koren G, Nulman I. Teratogenicity of lamotrigine. Can Fam Physician 2007; 53: 1007-1009.
264. Viguera AC, Whitfield T, Baldessarini RJ et al. Risk of recurrence in women with bipolar disorder during pregnancy: Prospective study of mood stabilizer discontinuation. Am J Psychiatry 2007; 164: 1817-1824.
265. Padmanabhan R. Etiology, pathogenesis and prevention of neural tube defects. Congenit Anom (Kyoto) 2006; 46: 55-67.
266. Perucca E. Age-related changes in pharmacokinetics: Predictability and assessment methods. Int Rev Neurobiol 2007; 81: 183-199.
267. Kaiser RM, Cohen HJ. Physiological and clinical considerations of geriatric patient care. in: Blazer DG, Steffens DC, Busse EW, ed. The American Psychiatric Publishing Textbook of Geriatric Psychiatry. Washington: American Psychiatric Publishing, Inc., 2004: 37-51.
268. Turnheim K. When drug therapy gets old: Pharmacokinetics and pharmacodynamics in the elderly. Exp Gerontol 2003; 38: 843-853.
269. Butler JM, Begg EJ. Free drug metabolic clearance in elderly people. Clin Pharmacokinet 2008; 47: 297-321.
270. Mulsant BH, Pollock BG. Psychopharmacology. In: Blazer DG, Steffens DC, Busse EW, ed. The American Psychiatric Publishing Textbook of Geriatric Psychiatry. Washington: American Psychiatric Publishing, Inc., 2004: 387-411.
271. Hardy BG, Shulman KI, Mackenzie SE, Kutcher SP, Silverberg JD. Pharmacokinetics of lithium in the elderly. J Clin Psychopharmacol 1987; 7: 153-158.
272. Sproule BA, Hardy BG, Shulman KI. Differential pharmacokinetics of lithium in elderly patients. Drugs Aging 2000; 16: 165-177.
273. Sajatovic M, Madhusoodanan S, Coconcea N. Managing bipolar disorder in the elderly: Defining the role of the newer agents. Drugs Aging 2005; 22: 39-54.
274. Nicoll SR, Sainsbury R, Bailey RR et al. Assessment of creatinine clearance in healthy subjects over 65 years of age. Nephron 1991; 59: 621-625.
275. Berman N, Hostetter TH. Comparing the Cockcroft-Gault and MDRD equations for calculation of GFR and drug doses in the elderly. Nat Clin Pract Nephrol 2007; 3: 644-645.
276. Mitchell JE, Mackenzie TB. Cardiac effects of lithium therapy in man: A review. J Clin Psychiatry 1982; 43: 47-51.
277. Roose SP, Nurnberger JI, Dunner DL, Blood DK, Fieve RR. Cardiac sinus node dysfunction during lithium treatment. Am J Psychiatry 1979; 136: 804-806.
278. Oudit GY, Korley V, Backx PH, Dorian P. Lithium-induced sinus node disease at therapeutic concentrations: Linking lithium-induced blockade of sodium channels to impaired pacemaker activity. Can J Cardiol 2007; 23: 229-232.
279. Rosenqvist M, Bergfeldt L, Aili H, Mathe AA. Sinus node dysfunction during long-term lithium treatment. Br Heart J 1993; 70: 371-375.
280. Ramsay RE, Rowan AJ, Pryor FM. Special considerations in treating the elderly patient with epilepsy. Neurology 2004; 62 (Suppl. 2): S24-S29.
281. Kasarskis EJ, Kuo CS, Berger R, Nelson KR. Carbamazepine-induced cardiac dysfunction. Characterization of two distinct clinical syndromes. Arch Intern Med 1992; 152: 186-191.
282. Kenneback G, Bergfeldt L, Vallin H, Tomson T, Edhag O. Electrophysiologic effects and clinical hazards of carbamazepine treatment for neurologic disorders in patients with abnormalities of the cardiac conduction system. Am Heart J 1991; 121: 1421-1429.
283. Perucca E, Aldenkamp A, Tallis R, Kramer G. Role of valproate across the ages. Treatment of epilepsy in the elderly. Acta Neurol Scand Suppl 2006; 184: 28-37.
284. Sajatovic M, Ramsay E, Nanry K, Thompson T. Lamotrigine therapy in elderly patients with epilepsy, bipolar disorder or dementia. Int J Geriatr Psychiatry 2007; 22: 945-950.
285. Saetre E, Perucca E, Isojarvi J, Gjerstad L. An international multicenter randomized double-blind controlled trial of lamotrigine and sustained-release carbamazepine in the treatment of newly diagnosed epilepsy in the elderly. Epilepsia 2007; 48: 1292-1302.
286. Kryzhanovskaya LA, Jeste DV, Young CA et al. A review of treatment-emergent adverse events during olanzapine clinical trials in elderly patients with dementia. J Clin Psychiatry 2006; 67: 933-945.
287. Wooltorton E. Risperidone (Risperdal): Increased rate of cerebrovascular events in dementia trials. CMAJ 2002; 167: 1269-1270.
288. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: Meta-analysis of randomized placebo-controlled trials. JAMA 2005; 294: 1934-1943.
289. Wang PS, Schneeweiss S, Avorn J et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med 2005; 353: 2335-2341.
290. U.S. Food and Drug Administration. FDA Public Health Advisory. Deaths with antipsychotics in elderly patients with behavioural disturbances. 2005 (cited 2008 December 30); available from: http://www.fda.gov/CDER/ drug/advisory/antipsychotics.htm.
291. O'Connor PJ, Crain AL, Rush WA, Sperl-Hillen JM, Gutenkauf JJ, Duncan JE. Impact of an electronic medical record on diabetes quality of care. Ann Fam Med 2005; 3: 300-306.
292. West E. Organisational sources of safety and danger: Sociological contributions to the study of adverse events. Qual Health Care 2000; 9: 120-126.
293. Kennedy A, Tapp A, Kelly WS, Kilzieh N, Wood AE. Abstinence, anticipation, reduction, and treatment (AART): A stepwise approach to the management of atypical antipsychotic side effects. Essent Psychopharmacol 2006; 7: 1-14.
294. Haynes RB, McDonald HP, Garg AX. Helping patients follow prescribed treatment: Clinical applications. JAMA 2002; 288: 2880-2883.
295. Mueser KT, Bond GR, Drake RE, Resnick SG. Models of community care for severe mental illness: A review of research on case management. Schizophr Bull 1998; 24: 37-74.
296. Swartz MS, Swanson JW, Wagner HR, Burns BJ, Hiday VA, Borum R. Can involuntary outpatient commitment reduce hospital recidivism? Findings from a randomized trial with severely mentally ill individuals. Am J Psychiatry 1999; 156: 1968-1975.
297. Lin D, Mok H, Yatham LN. Polytherapy in bipolar disorder. CNS Drugs 2006; 20: 29-42.
298. Borrelli D, Armistead M, Calkins A et al. The value of routine laboratory monitoring in a bipolar specialty clinic. In Program and abstracts of the 159th Annual Conference for the American Psychiatric Association; May 20-25, 2006. Toronto, Canada. Poster NR 181.